AdVax is a company that is well positioned, developing a new suite of diagnostics, therapeutics, healthcare management tools, vaccines, and monoclonal antibodies in the emerging multi-billion dollar arena of oral-systemic biology. Newly discovered links between two unique oral bacterial pathogens and chronic debilitating systemic illnesses are the basis for AdVax’s groundbreaking solutions for mul
tiple systemic diseases—including Alzheimer’s disease and cardiovascular diseases. Insurance company studies have shown that the fastest way to improve lives and reduce healthcare costs is to address the impact of oral inflammation on systemic disease. AdVax and its principals have identified the most pathogenic strains of two unique pathogens of oral origin. These pathogens have been profoundly shown to play a pathogenic role in Alzheimer’s disease; multiple cardiovascular diseases; neurodegenerative diseases including glaucoma; orodigestive cancers including esophageal and pancreatic cancers; failing arthritic knees; and potentially initiating rheumatoid arthritis. If these pathogens are left unaddressed, lives and society will continue down the path of out-of-control healthcare costs and unmitigated disease.
